Crossmark

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema

Crossref DOI link: https://doi.org/10.1186/s12348-019-0168-9

Published Online: 2019-01-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weber, Lea F.

Marx, Stefanie

Auffarth, Gerd U.

Scheuerle, Alexander F.

Tandogan, Tamer

Mayer, Christian

Khoramnia, Ramin
Funding

Funding for this research was provided by:

Alimera (Travel grants, Lecture fees, travel grants)

Allergan (Lecture fees, travel grants, Lecture fees, travel grants)
License Information

Text and Data Mining valid from 2019-01-29
More Information

Article History

Received: 4 September 2018

Accepted: 4 January 2019

First Online: 29 January 2019

Ethics approval and consent to participate

: Institutional review board, Ruprecht-Karls-Universität Heidelberg.The patients have consented to the submission of their cases to the journal.

: WL received travel grants from Alimera. MC received lecture fees and travel grants from Allergan. KR received lecture fees and travel grants from Allergan and Alimera. MS, AG, SA, and TT report no relevant disclosures.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.